Thanks to the perfect mastery of the regulatory environment and the diversity of experience of its partners in international laboratories and in firms dedicated to the health industries, ELSI has developed a recognized expertise in the practice of pharmaceutical business law.
From their experience alongside experts in the sector, as well as their complementary field and litigation practice, ELSI's partners have developed a sharp know-how and a pragmatic and innovative approach to pharmaceutical business cases.
Their mastery of competition and distribution law as well as business and commercial policies provides ELSI's clients with a comprehensive, strategic and transversal support in all these matters.
For example, the firm has been involved on several occasions in issues of co-marketing, risky launches, unfair competition, breach of commercial relations as well as in the negotiation and implementation of supplier and distributor contracts on a national and international level, for the whole of the pharmaceutical, veterinary and medical device sectors.
Anchored in the sectoral practice of their clients, ELSI's lawyers cultivatea modern approach and field expertise to respond as closely as possible to the needs of its clients.
In this respect, ELSI offers tailor-made support based on a dual approach combining advice and litigation, integrating risk analysis and anticipation, with the desire to provide a clear and strategic vision of all the problems encountered.
Whether it is a one-off question or a long-term management issue, the firm provides a tailor-made response and support adapted to the economic and commercial activity of its clients, in full transparency and predictability of its fee policy.
A true day-to-day partner, the firm offers integrated legal advice solutions, adapted according to needs, in the form of subscriptions, and co-piloting of certain subjects, with high profitability for the company.
Marketing, advertising, health police, establishments, anti-gift & transparency+
Commercial litigation, defective products, appeals against authorities' decisions, communication & crisis management+
GDPR, CNIL methodology, health data hosting
securing contracts, support for digital projects
Legal and regulatory updates, skills upgrading, find out about all our customised training offers+
Our outsourcing offer, the subcontracting of your anti-gift activities & health transparency+
Subscriptions, regulatory advice, audit packages, find all our subscription and subcontracting offers+
Transformation, temporary surge, implementation of new processes or crisis management+
An investigation by the DGCCRF in 2021 led to the penalization of 6.6 million euros for illegal practices by the URGO group.
Medical device law
An amendment to the WDR has just been proposed by the European Commission to postpone the entry into force of the WDR.